Drug intelligence / Profile preview

HBV-001

Development stage: Phase 1
Lead developer: Hawaii Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HBV-001 D1 is a biological component of the DEN1-80E vaccine, which is being developed by Hawaii Biotech, Inc. The DEN1-80E vaccine is administered intramuscularly and is undergoing Phase 1 clinical trials to assess its safety and tolerability in healthy adult subjects. While the 'HBV' prefix typically suggests Hepatitis B, the context explicitly links HBV-001 D1 to the DEN1-80E vaccine, indicating its use in a Dengue vaccine formulation.

Beyond the preview

Go deeper on HBV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBV-001.

Explore the full profile